MedTrace Logo

The Effect of Itraconazole on BCT197 Exposure in Healthy Male Participants

NCT03498170 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2018-05-18

No results posted yet for this study

Summary

An Open-label, 2-period, Single-sequence, Crossover Study to Evaluate the Effect of Multiple Oral Dosing of Itraconazole on BCT197 Systemic Exposure in Healthy Male Participants.

Conditions

  • Interaction

Interventions

DRUG

BCT197

Single dose of BCT197

DRUG

Itraconazole 200 mg

Single dose of itraconazole

Sponsors & Collaborators

  • Mereo BioPharma

    lead INDUSTRY

Principal Investigators

  • Jacqueline Parkin, PhD FRCP · Mereo BioPharma

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-03-19
Primary Completion
2018-05-03
Completion
2018-05-09
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03498170 on ClinicalTrials.gov